Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity

  title={Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity},
  author={Houman Alimoradi and Khaled Greish and Anita Barzegar-fallah and Lama Alshaibani and Valeria Pittal{\`a}},
  journal={International Journal of Nanomedicine},
  pages={7771 - 7787}
Purpose Anticancer drug delivery systems are often limited by hurdles, such as off-target distribution, slow cellular internalization, limited lysosomal escape, and drug resistance. To overcome these limitations, we have developed a stable nitric oxide (NO)-releasing nanoparticle (polystyrene-maleic acid [SMA]-tert-dodecane S-nitrosothiol [tDodSNO]) with the aim of enhancing the anticancer properties of doxorubicin (Dox) and a Dox-loaded nanoparticle (SMA-Dox) carrier. Materials and methods… Expand
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
The roles of nanoparticles and hybrid nanoparticles for drug delivery in chemotherapy, targeted therapy, and immunotherapy are discussed and the targeting mechanism of nanoparticle-based drug delivery as well as its function on reversing drug resistance are described. Expand
Nitric Oxide-Releasing Polymeric Materials for Antimicrobial Applications: A Review
This review highlights approaches to delivery NO from different types of polymeric materials for combating diseases caused by pathogenic bacteria, which hopefully can inspire researchers facing common challenges in the coming ‘post-antibiotic’ era. Expand
Mitochondrial dysfunction, autophagy stimulation and non-apoptotic cell death caused by nitric oxide-inducing Pt-coated Au nanoparticle in human lung carcinoma cells.
Pt coated Au NP caused NO-dependent mitochondrial dysfunction and autophagy and mode of cell death due to NP was much different from ROS-inducing cisplatin. Expand
Controlled Delivery of Nitric Oxide for Cancer Therapy
The effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy are covered. Expand
Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment
Intensive efforts have been made for exploring cell-membrane coated nanoparticles and immune cell-targeted nanoparticles (immunotherapy) to modulate the tumor microenvironment and deliver accurate amounts of therapeutic agents to TNBC without stimulating the immune system. Expand
Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs.
The role and underlying mechanisms by which nitric oxide donors sensitize cancer resistant cells to both chemotherapy and immunotherapy are briefly described. Expand
Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
A dual-functional Pt(iv) prodrug, Pt-furoxan, can release cytotoxic cisplatin and signaling molecule NO upon cellular internalization, leading to a synergistic anti-proliferation effect and a promising anti-metastasis effect both in vitro and in vivo. Expand


Nitric oxide releasing d-α-tocopheryl polyethylene glycol succinate for enhancing antitumor activity of doxorubicin.
This new NO donor, TNO3, may provide a simple but effective strategy to enhance the therapeutic efficacy of chemotherapeutic drugs. Expand
SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours.
Data indicate that i.v. administration of SMA-Dox micellar formulation can enhance the therapeutic effect of doxorubicin while reducing greatly cardiac and bone marrow toxicity, which should allow safe use of high doses of this agent. Expand
Controllable release of nitric oxide and doxorubicin from engineered nanospheres for synergistic tumor therapy.
This study highlights the controllable release of NO and DOX from the same nanocarriers and the synergistic therapeutic effect on tumors, which could give new insights into improving cancer nanotherapeutics. Expand
Size-Dependent Endocytosis of Nanoparticles.
A thermodynamic model for receptor-mediated endocytosis of ligand-coated NPs is presented, and an optimal NP radius is identified at which the cellular uptake reaches a maximum of several thousand at physiologically relevant parameters, and it is shown that the cell uptake is regulated by membrane tension, and can be elaborately controlled by particle size. Expand
Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.
The results suggest that onset of MDR and impairment of NO synthesis are related; this finding could point to a new strategy to reverse doxorubicin resistance in human cancer. Expand
Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy
The mechanism of NO in overcoming MDR and recent progress of combined NO and drug delivery systems are discussed. Expand
Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
S-nitrosated human serum albumin dimer (SNO-HSA Dimer) could enhance the therapeutic effect of nab-PTX even in low vascular permeability or intractable pancreatic cancers. Expand
Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer
This work highlights the effect of Sildenafil on tumour vasculatures and provides a rational for further testing the combination on breast cancer patients. Expand
Doxil®--the first FDA-approved nano-drug: lessons learned.
  • Y. Barenholz
  • Medicine
  • Journal of controlled release : official journal of the Controlled Release Society
  • 2012
This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use and demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles. Expand
Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide
In colon 26 (C26) cells, SNO‐HSA significantly suppressed hypoxia‐induced autophagy by inhibiting the phosphorylation of JNK1 and the expression of its downstream molecule Beclin1, and in vivo, the immunostaining of tumor tissues clearly showed that SNO-HSA inhibited the autophagic of tumor cells induced by bevacizumab treatment. Expand